D Spending

Corporate restructurings are forcing some U.S. companies to curtail R&D spending even as they are being urged to increase such investments to remain competitive. Many companies, saddled by the massive debts often involved in such transactions, are having "to change their business strategy from long-term to shorter-term cash flow, which can't help but have an adverse effect on R&D," said Roland W. Schmitt, senior vice president and chief scientist at General Electric and chairman of NSF's Nationa

Written byStephen Greene
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Many companies, saddled by the massive debts often involved in such transactions, are having "to change their business strategy from long-term to shorter-term cash flow, which can't help but have an adverse effect on R&D," said Roland W. Schmitt, senior vice president and chief scientist at General Electric and chairman of NSF's National Science Board. "I think there's no question that the whole business of acquisitions, mergers and takeovers will result in lower R&D expenditures."

Charles Larson, executive director of the Industrial Research Institute in New York, fears what he sees as a growing trend.

"It's the result of the drive to maximize the bottom line every quarter, rather than taking a long range viewpoint, and that's very unfortunate," Larson said. "It is just the opposite of what we should be doing at this time … I don't think it can help our competitiveness, particularly when you look at what ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies